Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jul;21(7):1456-63.
doi: 10.1038/mt.2013.79. Epub 2013 May 14.

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma

Chuanliang Cui  1 , Lili Mao, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Siming Li, Bin Lian, Kangsheng Gu, Min Tao, Xin Song, Tongyu Lin, Xiubao Ren, Shukui Qin, Jun Guo
Affiliations
Clinical Trial

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma

Chuanliang Cui et al. Mol Ther. 2013 Jul.

Abstract

Endostatin is a potent endogenous angiogenic inhibitor with implicated antitumor activity. However, efficacy of recombinant human endostatin (rhES) in clinical trials is controversial, and application of rhES in treatment of metastatic melanoma awaits further investigations. This phase II trial evaluated the efficacy and safety of a soluble and stable rhES (Endostar) plus dacarbazine in patients with metastatic melanomas that contains no mutations in c-kit and BRAF genes. A total of 110 patients received placebo plus dacarbazine (250 mg/m², n = 54) or Endostar (7.5 mg/m²) plus dacarbazine (250 mg/m², n = 56). The primary end points were progression-free survival (PFS) and overall survival (OS). Median PFS in the Endostar plus dacarbazine arm was 4.5 months versus 1.5 months in the placebo plus dacarbazine arm (hazard ratio (HR) = 0.578; P = 0.013). There were statistically significant improvements in OS (median, 12.0 months versus 8.0 months; HR, 0.522; P = 0.005) in favor of the Endostar plus dacarbazine arm. The regimen was generally well tolerated and had a manageable toxicity profile. Our trial suggests that Endostar plus dacarbazine is well tolerated in patients with metastatic melanoma harboring no genetic mutations popular for targeted therapy and yields a significant improvement in PFS and OS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram.
Figure 2
Figure 2
Kaplan–Meier estimated survival for all patients by treatment groups. (a) progression-free survival and (b) overall survival for all patients. CI, confidence interval; D, dacarbazine; E, Endostar; HR, hazard ratio; OS, overall survival; P, placebo; PFS, progression-free survival.
Figure 3
Figure 3
Kaplan–Meier estimated survival for patients with poor prognosis by treatment groups. (a) progression-free survival and (b) overall survival for patients with elevated serum lactate dehydrogenase levels. CI, confidence interval; D, dacarbazine; E, Endostar; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; P, placebo; PFS, progression-free survival.
Figure 4
Figure 4
Analysis of progression-free survival and overall survival by subgroups for all randomly assigned patients. (a) Progression-free survival (PFS); (b) overall survival (OS). CI, confidence interval; CSD, melanomas on skin with chronic sun-induced damage; NCSD, melanomas on skin without chronic sun-induced damage; ULN, upper limit of the normal range; UP, melanoma of unknown primary.
See this image and copyright information in PMC

References

    1. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:1743–1751. - PubMed
    1. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–166. - PubMed
    1. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118–1125. - PubMed
    1. Seetharamu N, Ott PA, Pavlick AC. Novel therapeutics for melanoma. Expert Rev Anticancer Ther. 2009;9:839–849. - PubMed
    1. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–714. - PMC - PubMed

Publication types